533 research outputs found

    Uma utopia brasileira: Vargas e a construção do estado de bem-estar numa sociedade estruturalmente desigual

    Full text link

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

    Arsenic Exposure Increases Monocyte Adhesion to the Vascular Endothelium, a Pro-Atherogenic Mechanism

    No full text
    Epidemiological studies have shown that arsenic exposure increases atherosclerosis, but the mechanisms underlying this relationship are unknown. Monocytes, macrophages and platelets play an important role in the initiation of atherosclerosis. Circulating monocytes and macrophages bind to the activated vascular endothelium and migrate into the sub-endothelium, where they become lipid-laden foam cells. This process can be facilitated by platelets, which favour monocyte recruitment to the lesion. Thus, we assessed the effects of low-to-moderate arsenic exposure on monocyte adhesion to endothelial cells, platelet activation and platelet-monocyte interactions. We observed that arsenic induces human monocyte adhesion to endothelial cells in vitro. These findings were confirmed ex vivo using a murine organ culture system at concentrations as low as 10 ppb. We found that both cell types need to be exposed to arsenic to maximize monocyte adhesion to the endothelium. This adhesion process is specific to monocyte/endothelium interactions. Hence, no effect of arsenic on platelet activation or platelet/leukocyte interaction was observed. We found that arsenic increases adhesion of mononuclear cells via increased CD29 binding to VCAM-1, an adhesion molecule found on activated endothelial cells. Similar results were observed in vivo, where arsenic-exposed mice exhibit increased VCAM-1 expression on endothelial cells and increased CD29 on circulating monocytes. Interestingly, expression of adhesion molecules and increased binding can be inhibited by antioxidants in vitro and in vivo. Together, these data suggest that arsenic might enhance atherosclerosis by increasing monocyte adhesion to endothelial cells, a process that is inhibited by antioxidants

    Arsenic-induced monocyte adhesion to VCAM-1 is prevented by antioxidant <i>in vitro</i>.

    No full text
    <p>U937 cells (1000 cells/ml) were pretreated for 1 h with NAC (1 mM) and then exposed to arsenic for 3h (0, 10, 50 or 200 ppb). Cells were stained with HEt and staining detected by flow cytometry (A). Alternatively, cells were fluorescently-labelled with orange tracker and incubated on VCAM-1/Fc coated plates (B). The non-adherent cells were washed away, and the adherent fluorescent cells were counted. Values are expressed as mean ± S.D., n ≥ 3. * p < 0.05: **: p < 0.01; ***: p < 0.001, compared to unexposed controls.</p

    Arsenic increases adhesion molecule expression <i>in vivo</i>, which can be prevented by addition of high selenium diet.

    No full text
    <p>(A-B) In order to evaluate <i>in vivo</i> effects of arsenic, five-week-old male apoE<sup>-/-</sup> mice fed normal rodent diet were exposed to arsenic (200 ppb) for 13 weeks or maintained on tap water. Carotids were stained for VCAM-1 (A) and whole blood was collected and CD29 expression was detected using flow-cytometry (B). (C-F) In order to evaluate ROS involvement in arsenic-induced atherosclerosis, five-week-old male apoE<sup>-/-</sup> mice were exposed to arsenic (200 ppb) for 13 weeks or maintained on tap water. Mice were fed with low selenium or high selenium chow. Carotids were stained for ROS (C), or VCAM-1 (D). Blood was collected and CD29 expression was detected using flow-cytometry (E), or cells were fluorescently-labelled and incubated on VCAM-1/Fc coated plates (F). Values are expressed as mean ± S.D., n ≥ 3. * p < 0.05: **: p < 0.01; ***: p < 0.001, compared to unexposed controls.</p

    Arsenic does not enhance platelet activation, platelet/monocyte interaction or platelet/neutrophil aggregates formation.

    No full text
    <p>C57BL/6 wild-type and apoE<sup>-/-</sup> mouse platelets were collected and exposed to arsenic (10, 50 or 200 ppb) and/or thrombin for 5 minutes. Representative pictures of platelet spreading after control, 200 ppb arsenic or 1U thrombin are shown in A (left panels: C57BL/6; right panels: apoE<sup>-/-</sup>). (B) P-selectin (CD62) expression was assessed by flow cytometry (up panel: C57BL/6; down panel: apoE<sup>-/-</sup>). (C) Circulating CCL5 levels were measured in apoE<sup>-/-</sup> male mice were left untreated or exposed to 200 ppb arsenic for 8 or 13 weeks using an immunoassay kit (multiplex bead-based) on a Bio-Plex 200 (Bio-Rad Laboratories, ON, Canada). Each sample (n = 4) was analyzed in duplicate (technical replicate). (D-E) The platelet/monocyte aggregates (CD14<sup>+</sup>/CD41<sup>+</sup>; D) and the platelet/neutrophil aggregates (Ly6G<sup>+</sup>/CD41<sup>+</sup>; E) were followed from day 14 to 28 in the circulation of mice exposed to 200 ppb arsenic. One mouse, as positive control, was treated with LPS for 18 hours before the blood collection. Values are expressed as mean ± S.D., n ≥ 3 animals.</p

    Arsenic increases adhesion of mononuclear cells via increased CD29 binding to VCAM-1.

    No full text
    <p>U937 or human PBMC cells (1000 cells/ml) were exposed to arsenic for 72h (0, 10 or 200 ppb) (A). Cells were fluorescently-labelled and incubated on VCAM-1/Fc coated plates. The non-adherent cells were washed away, and adherent fluorescent cells were counted. In B, cellular surface CD29 antigens were detected by flow-cytometry using anti-CD29 antibody. (C-D) CD29 blocking antibody was added to <i>in vitro</i> U937 binding assays to VCAM-1/Fc (C) or to <i>ex vivo</i> organ cultures with primary mononuclear cells (D). Values are expressed as mean ± S.D., n ≥ 3. * p < 0.05: **: p < 0.01; ***: p < 0.001, compared to unexposed controls.</p

    Arsenic induces monocyte adhesion to endothelial cells, with maximal binding achieved following exposure of both cell types.

    No full text
    <p>(A) U937 and/or HUVEC cells (1000 cells/ml) were exposed to arsenic overnight (0, 10 or 200 ppb). U937 cells were fluorescently-labelled and were incubated with HUVEC cells. The non-adhered cells were washed away, and the adherent fluorescent cells were counted. Data are expressed as relative number of U937 over total HUVEC stained cells. ** = p<0.01; *** = p<0.001 B) Representative pictures are shown (40X). C-D) Organ culture of carotid arteries and fluorescently-labelled bone marrow cells where neither, one, or both components were exposed to arsenic trioxide overnight and allowed to adhere to each other for 30 min before being washed. Adherent cells were counted. Representative pictures of 200 ppb arsenic-exposed are shown in C. D) Both components were exposed to either 10 or 200 ppb arsenic. Data represent ratio ± S.D., n ≥ 3. **: p < 0.01; ***: p < 0.001, compared to unexposed controls.</p
    corecore